Olsalazine - CAS 15722-48-2
Catalog number: 15722-48-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C14H10N2O6
Molecular Weight:
302.24
COA:
Inquire
Targets:
Lipoxygenases (LOXs)
Description:
Olsalazine, a kind of colchicum alkaloid, has been found to be an anti-inflammatory agent and could be used against inflammatory bowel disease and ulcerative colitis.
Purity:
98%
Appearance:
Powder
Synonyms:
OLSALAZINE;3,3’-azobis(6-hydroxy-benzoicaci;3,3’-azobis(6-hydroxybenzoicacid);5,5’-azobis(salicylicacid);azodisal;c.i.mordantyellow5;Ph-CJ-91B;4,4'-Dihydroxyazobenzene-3,3'-dicarboxylic acid
Storage:
Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).
MSDS:
Inquire
Quality Standard:
In-house standard
Quantity:
Milligram-Grams
Density:
1.550 g/cm3
InChIKey:
ULGVHUUBIHTFAM-PXNMLYILSA-N
InChI:
InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,15,17H,(H,19,20)(H,21,22)/b16-8-
Canonical SMILES:
C1=CC(=C(C=C1NN=C2C=CC(=O)C(=C2)C(=O)O)C(=O)O)O
1.Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a cellular context.
Méndez-Lucio O1, Tran J, Medina-Franco JL, Meurice N, Muller M. ChemMedChem. 2014 Mar;9(3):560-5. doi: 10.1002/cmdc.201300555. Epub 2014 Jan 31.
DNA hypomethylating drugs that act on DNA methyltransferase (DNMT) isoforms are promising anticancer agents. By using a well-characterized live-cell system to measure DNA methylation revisions (imprints), we characterize olsalazine, an approved anti-inflammatory drug, as a novel DNA hypomethylating agent. The cell-based screen used in this work is highly tractable, internally controlled, and well-suited for a drug repurposing strategy in epigenetics. Olsalazine very closely mimics the action of 5-aza-2'-deoxycytidine, a known hypomethylating drug, with minimal cytotoxicity at the concentrations tested. Olsalazine was identified by a rapid computer-guided similarity search of a database of approved drugs to a previously identified inhibitor of DNMTs.
2.Technetium-99 m labeling and evaluation of olsalazine: a novel agent for ulcerative colitis imaging.
El-Kawy OA1, Ibrahim IT1, Farah K1. J Labelled Comp Radiopharm. 2015 Jun 30;58(8):336-41. doi: 10.1002/jlcr.3306. Epub 2015 Jun 1.
Ulcerative colitis is a chronic disease having a regressive nature. Commonly used diagnostic methods have the disadvantage to be invasive, time-consuming, and expensive. Therefore, a new sensitive method for the detection and monitoring of disease activity is urgently needed in clinical practice. In the current investigation, radio complexation of olsalazine with technetium-99m, its characterization, and optimization of the labeling conditions were explored. Optimum radiochemical yield of (99m) Tc-olsalazine (97.6% ± 1.8%) was obtained via direct complexation with technetium-99m (~200 MBq) in the presence of stannous chloride dihydrate (100 µg) as reducing agent at pH 6. It was observed that the complex showed significant in vitro stability in serum at 37°C for more than 11 h. The computer-generated optimized geometries of the (99m) Tc-olsalazine were reported, and biodistribution studies were carried out using chemically and microbiologically mice-induced ulcerative colitis models.
3.Treating TNBS-induced colitis in rats with probiotics.
Wan YM1, Zhu YQ, Xia B, Luo J. Turk J Gastroenterol. 2011 Oct;22(5):486-93.
BACKGROUND/AIMS: We aimed to investigate the therapeutic effects of Peifeikang, a probiotics compound, on colitis in rats induced by trinitrobenzene sulfonic acid and to elucidate its potential mechanism.
4.Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
Sann H1, Erichsen Jv, Hessmann M, Pahl A, Hoffmeyer A. Life Sci. 2013 Apr 9;92(12):708-18. doi: 10.1016/j.lfs.2013.01.028. Epub 2013 Feb 8.
AIMS: Although acute dextran sodium sulphate (DSS)-induced colitis in mice is frequently used as a preclinical model for testing drugs involved in inflammatory bowel disease (IBD), only limited data is available that compares the efficacy of established drug treatments and combinations employed in IBD. We have therefore compared the efficacy of aminosalicylates (mesalazine, olsalazine), corticosteroids (budesonide), thiopurines (6-thioguanine (6-TG)) and cyclosporine A (CsA) and combinations thereof as well as the EP4 agonist AGN205203 in the acute DSS-colitis model.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Lipoxygenases (LOXs) Products


CAS 154355-76-7 Atreleuton

Atreleuton
(CAS: 154355-76-7)

Atreleuton, a kind of urea compound, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene B4 receptor antagonist that could probably be useful...

CAS 847163-28-4 ML 351

ML 351
(CAS: 847163-28-4)

ML 351 is a potent and selective inhibitor of 12/15-lipoxygenase (IC50 value 200 nM against human 12/15-LOX), which catalyzes the oxidation of polyunsaturated f...

CAS 132392-39-3 LY 221068

LY 221068
(CAS: 132392-39-3)

LY 221068 is a Lipoxygenase inhibitor originated by Eli Lilly. It is a potent antioxidant with antiinflammatory properties. But no development was reported for ...

CAS 169626-43-1 WAY-126299A

WAY-126299A
(CAS: 169626-43-1)

WAY-126299A, a benzothiazoly derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist and was once studied in A...

CAS 132465-10-2 2-TEDC

2-TEDC
(CAS: 132465-10-2)

2-TEDC is a potent inhibitor of 5-, 12-, and 15-lipoxygenase (IC50 = 0.09, 0.013 and 0.5 μM, respectively).

CAS 15722-48-2 Olsalazine

Olsalazine
(CAS: 15722-48-2)

Olsalazine, a kind of colchicum alkaloid, has been found to be an anti-inflammatory agent and could be used against inflammatory bowel disease and ulcerative co...

CAS 155944-23-3 ZM-230487

ZM-230487
(CAS: 155944-23-3)

ZM-230487, a quinolin derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist. It was once studied in anti-inf...

CAS 175212-04-1 CMI-977

CMI-977
(CAS: 175212-04-1)

CMI-977, an oxolan compound, has been found to be a 5-Lipoxygenases inhibitor and was once studied as an antiasthmatic agent.

Chemical Structure

CAS 15722-48-2 Olsalazine

Quick Inquiry

Verification code

Featured Items